Find Raloxifene Hydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

264RELATED EXCIPIENT COMPANIES

460EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 82640-04-8, Raloxifene hcl, Evista, Keoxifene hydrochloride, Keoxifene, Optruma
Molecular Formula
C28H28ClNO4S
Molecular Weight
510.0  g/mol
InChI Key
BKXVVCILCIUCLG-UHFFFAOYSA-N
FDA UNII
4F86W47BR6

Raloxifene Hydrochloride
A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.
1 2D Structure

Raloxifene Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone;hydrochloride
2.1.2 InChI
InChI=1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29;/h4-13,18,30-31H,1-3,14-17H2;1H
2.1.3 InChI Key
BKXVVCILCIUCLG-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl
2.2 Other Identifiers
2.2.1 UNII
4F86W47BR6
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Evista

2. Keoxifene

3. Keoxifene Hydrochloride

4. Ly 139481

5. Ly 156758

6. Ly-139481

7. Ly-156758

8. Ly139481

9. Ly156758

10. Raloxifene

11. Raloxifene Hcl

2.3.2 Depositor-Supplied Synonyms

1. 82640-04-8

2. Raloxifene Hcl

3. Evista

4. Keoxifene Hydrochloride

5. Keoxifene

6. Optruma

7. Raloxifene Teva

8. (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone Hydrochloride

9. Raloxifene (hydrochloride)

10. Ly 156758

11. Ly156758

12. Ly-156758

13. Nsc-706725

14. 2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol Hydrochloride

15. Chebi:50740

16. Evista (raloxifene Hydrochloride)

17. 4f86w47br6

18. 6-hydroxy-2-(p-hydroxyphenyl)benzo(b)thien-3-yl-p-(2-piperidinoethoxy)phenyl Ketone, Hydrochloride

19. Dsstox_cid_14181

20. Dsstox_rid_79119

21. Dsstox_gsid_34181

22. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride

23. [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone;hydrochloride

24. Smr000058508

25. Raloxifene Hydrochloride [usan]

26. Ncgc00015889-05

27. Cas-82640-04-8

28. C28h27no4s.hcl

29. Loxifen

30. Unii-4f86w47br6

31. Sr-01000076102

32. Cdt-raloxifene

33. Raloxifene-d4 Hcl

34. Raloxifene Cloridrato

35. Evista (tn)

36. Mfcd01938233

37. Prestwick_1035

38. Raloxifene Hydrochloride [usan:usp]

39. Methanone, Hydrochloride

40. Cloridrato De Raloxifeno

41. Clorhidrato De Raloxifeno

42. Chlorhydrate De Raloxifene

43. Ly139481 Hydrochloride

44. Ly156758 Hydrochloride

45. Chembl1116

46. Schembl19077

47. Mls000859902

48. Mls001332533

49. Mls001332534

50. Mls002222293

51. Raloxifene Hydrochloride, Solid

52. Evista, Raloxifene Hydrochloride

53. Raloxifene Hydrochloride- Bio-x

54. Dtxsid1034181

55. Ly156758 (keoxifene) Hcl

56. Ly-139481 Hcl

57. Hms1570n05

58. Pharmakon1600-01505622

59. Amy23426

60. Bcp05713

61. Raloxifene Hydrochloride (jan/usp)

62. Tox21_110255

63. Tox21_302369

64. Tox21_501051

65. Hy-13738a

66. Nsc706725

67. Nsc759285

68. Raloxifene Hydrochloride [mi]

69. S1227

70. Raloxifene Hydrochloride [jan]

71. Akos008131940

72. Tox21_110255_1

73. Ac-8390

74. Ccg-213497

75. Cs-1775

76. Ds-2162

77. Ks-1102

78. Lp01051

79. Nc00665

80. Nsc 706725

81. Nsc 759285

82. Nsc-759285

83. Raloxifene Hydrochloride [mart.]

84. Raloxifene Hydrochloride [vandf]

85. Ncgc00015889-03

86. Ncgc00015889-11

87. Ncgc00092353-01

88. Ncgc00092353-03

89. Ncgc00094334-01

90. Ncgc00094334-02

91. Ncgc00255153-01

92. Ncgc00261736-01

93. Raloxifene Hydrochloride [usp-rs]

94. Raloxifene Hydrochloride [who-dd]

95. Br164310

96. Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-, Hydrochloride

97. Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-,hydrochloride (1:1)

98. Raloxifene Hydrochloride [ema Epar]

99. Eu-0101051

100. Ft-0630912

101. R0109

102. Sw197106-5

103. En300-52517

104. Raloxifene Hydrochloride [orange Book]

105. D02217

106. R 1402

107. Raloxifene Hydrochloride [ep Monograph]

108. Raloxifene Hydrochloride [usp Impurity]

109. Raloxifene Hydrochloride [usp Monograph]

110. 640r048

111. A840401

112. Q-201656

113. Sr-01000076102-2

114. Sr-01000076102-9

115. Q27122215

116. (6-oxo-1,6-dihydro-pyridazin-3-yloxy)-aceticacid

117. Raloxifene Hydrochloride, European Pharmacopoeia (ep) Reference Standard

118. Raloxifene Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

119. Raloxifene Hydrochloride, United States Pharmacopeia (usp) Reference Standard

120. (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)-(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone Hydrochloride

121. (6-oh-2-(4-oh-ph)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)ph)methanone Hydrochloride

122. [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone Hydrochloride

123. [6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride

124. [6-hydroxy-2-(4-hydroxyphenyl)benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride

125. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride

126. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone, Monohydrochloride

127. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride

128. [6-hydroxy-2[4-hydroxyphenyl)benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride

129. [6-hydroxy-2[4-hydroxyphenyl)benzo [b]thien3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride

130. [6-hydroxy-2[4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride

131. 1-[2-(4-{[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]carbonyl}phenoxy)ethyl]piperidinium Chloride

132. 6-hydroxy-2-(4-hydroxyphenyl)-3-[ 4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene, Hydrochloride

133. 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]-thiophene Hydrochloride

134. 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]thiophene Hydrochloride

135. 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl 4-[2-(1-piperidinyl)ethoxy]phenyl Methanone Hydrochloride

136. 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl 4-[2-(1-piperidinyl)ethoxy]phenyl Ketone Hydrochloride

137. 6-hydroxy-2-(p-hydroxyphenyl)benzo(.beta.)thien-3-yl-p-(2-piperidinoethoxy)phenyl Ketone, Hydrochloride

138. Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(.beta.)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-, Hydrochloride

139. Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-, Hydrochloride (1:1)

140. Raloxifene Hydrochloride For Peak Identification, European Pharmacopoeia (ep) Reference Standard

2.4 Create Date
2005-03-26
3 Chemical and Physical Properties
Molecular Weight 510.0 g/mol
Molecular Formula C28H28ClNO4S
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count6
Rotatable Bond Count7
Exact Mass509.1427572 g/mol
Monoisotopic Mass509.1427572 g/mol
Topological Polar Surface Area98.2 Ų
Heavy Atom Count35
Formal Charge0
Complexity655
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameEvista
PubMed HealthRaloxifene (By mouth)
Drug ClassesAntineoplastic Agent, Endocrine-Metabolic Agent
Drug LabelEVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m...
Active IngredientRaloxifene hydrochloride
Dosage FormTablet
Routeoral; Oral
Strength60mg
Market StatusPrescription
CompanyLilly

2 of 4  
Drug NameRaloxifene hydrochloride
Drug LabelEVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m...
Active IngredientRaloxifene hydrochloride
Dosage FormTablet
Routeoral; Oral
Strength60mg
Market StatusTentative Approval; Prescription
CompanyTeva Pharms Usa; Invagen Pharms; Watson Labs

3 of 4  
Drug NameEvista
PubMed HealthRaloxifene (By mouth)
Drug ClassesAntineoplastic Agent, Endocrine-Metabolic Agent
Drug LabelEVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m...
Active IngredientRaloxifene hydrochloride
Dosage FormTablet
Routeoral; Oral
Strength60mg
Market StatusPrescription
CompanyLilly

4 of 4  
Drug NameRaloxifene hydrochloride
Drug LabelEVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m...
Active IngredientRaloxifene hydrochloride
Dosage FormTablet
Routeoral; Oral
Strength60mg
Market StatusTentative Approval; Prescription
CompanyTeva Pharms Usa; Invagen Pharms; Watson Labs

4.2 Drug Indication

Optruma is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Optruma or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5. 1).


Evista is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.


Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.

When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Selective Estrogen Receptor Modulators

A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63) (See all compounds classified as Selective Estrogen Receptor Modulators.)


Bone Density Conservation Agents

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)


Estrogen Antagonists

Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Selective Estrogen Receptor Modulators [MoA]; Estrogen Agonist/Antagonist [EPC]
5.3 ATC Code

G03XC01


G03XC01


G03XC01


USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2013-04-02

Pay. Date : 2013-03-22

DMF Number : 16143

Submission : 2002-09-23

Status : Active

Type : II

Dr Reddy Company Banner

02

Tapi Nl Bv

Israel
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2014-04-29

Pay. Date : 2014-02-24

DMF Number : 27969

Submission : 2014-03-17

Status : Active

Type : II

TAPI Company Banner

03

Aarti Drugs Ltd

India

USDMF

arrow
PEGS Boston Summit
Not Confirmed

03

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 21650

Submission : 2008-05-22

Status : Active

Type : II

blank

04

PEGS Boston Summit
Not Confirmed

04

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 24589

Submission : 2011-02-01

Status : Inactive

Type : II

blank

05

PEGS Boston Summit
Not Confirmed

05

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2016-07-05

Pay. Date : 2015-09-24

DMF Number : 22927

Submission : 2009-07-07

Status : Active

Type : II

blank

06

Cipla Ltd

India

USDMF

arrow
PEGS Boston Summit
Not Confirmed

06

Cipla Ltd

India
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 20163

Submission : 2007-01-17

Status : Inactive

Type : II

blank

07

Erregierre Spa

Italy

USDMF

arrow
PEGS Boston Summit
Not Confirmed

07

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2015-10-05

Pay. Date : 2015-09-25

DMF Number : 15932

Submission : 2002-04-10

Status : Active

Type : II

blank

08

PEGS Boston Summit
Not Confirmed

08

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2014-03-04

Pay. Date : 2013-09-05

DMF Number : 21682

Submission : 2008-06-05

Status : Active

Type : II

blank

09

Hetero Drugs Ltd

India

USDMF

arrow
PEGS Boston Summit
Not Confirmed

09

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2019-06-12

Pay. Date : 2018-05-25

DMF Number : 25281

Submission : 2011-09-06

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

read-more
read-moreread-more
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
R1-CEP 2014-054 - Rev 01
Valid
Chemical
2023-03-31
2375
Dr Reddy Company Banner

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Certificate Number : R1-CEP 2014-054 - Rev 01

Status : Valid

Issue Date : 2023-03-31

Type : Chemical

Substance Number : 2375

Dr Reddy Company Banner

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Certificate Number : CEP 2017-097 - Rev 01

Status : Valid

Issue Date : 2024-08-22

Type : Chemical

Substance Number : 2375

blank

03

PEGS Boston Summit
Not Confirmed
arrow

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Certificate Number : CEP 2012-016 - Rev 02

Status : Valid

Issue Date : 2024-01-05

Type : Chemical

Substance Number : 2375

blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Certificate Number : R1-CEP 2010-205 - Rev 00

Status : Valid

Issue Date : 2017-09-06

Type : Chemical

Substance Number : 2375

blank

06

PEGS Boston Summit
Not Confirmed
arrow

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Certificate Number : R1-CEP 2010-227 - Rev 01

Status : Valid

Issue Date : 2019-10-15

Type : Chemical

Substance Number : 2375

blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Certificate Number : R1-CEP 2011-349 - Rev 00

Status : Valid

Issue Date : 2020-11-30

Type : Chemical

Substance Number : 2375

blank

09

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Certificate Number : R0-CEP 2015-174 - Rev 00

Status : Withdrawn by Holder

Issue Date : 2016-11-02

Type : Chemical

Substance Number : 2375

blank

10

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Certificate Number : R1-CEP 2015-171 - Rev 00

Status : Valid

Issue Date : 2022-04-08

Type : Chemical

Substance Number : 2375

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-moreread-more

01

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene hydrochloride

Registration Number : 228MF10113

Registrant's Address : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad Telangana, India

Initial Date of Registration : 2016-06-17

Latest Date of Registration : 2016-06-17

blank

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene hydrochloride

Registration Number : 227MF10039

Registrant's Address : Via Curiel 34, 20067 Paulo, Milano, ITALY

Initial Date of Registration : 2015-02-09

Latest Date of Registration : 2015-02-09

blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride

Registration Number : 226MF10007

Registrant's Address : VIA F. BARACCA 19-24060 SAN PAOLO D'ARGON (BERGAMO) ITALY

Initial Date of Registration : 2014-01-08

Latest Date of Registration : 2014-11-17

blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene hydrochloride hydrate

Registration Number : 227MF10053

Registrant's Address : 57, Gyeongje-ro, Siheung-si, Gyeonggi-do, Korea

Initial Date of Registration : 2015-02-18

Latest Date of Registration : 2015-02-18

blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene hydrochloride hydrate

Registration Number : 227MF10048

Registrant's Address : 174, Sirok-ro, Asan-si, Chungcheongnam-do, KOREA

Initial Date of Registration : 2015-02-09

Latest Date of Registration : 2023-09-20

blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride

Registration Number : 303MF10064

Registrant's Address : Strada Rivoltana Km. 6/7 20053 Rodano (MI), Italy

Initial Date of Registration : 2021-04-13

Latest Date of Registration : 2021-04-13

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

Aarti Drugs

India
PEGS Boston Summit
Not Confirmed
arrow

Aarti Drugs

India
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride EP

Date of Issue : 2025-10-07

Valid Till : 2028-05-05

Written Confirmation Number : WC-0219

Address of the Firm : Plot No. E-22, MIDC Tarapur-Boisar, Thane-401506, Maharashtra, India

blank

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride Ph.Eur

Date of Issue : 2025-07-11

Valid Till : 2028-06-25

Written Confirmation Number : WC-0023

Address of the Firm : Sy. No\'s. 52,53,58,59,61 to 78, 127 & 128, Pydibhimavaram Village & Sy. No\'s. ...

blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride USP

Date of Issue : 2025-09-03

Valid Till : 2028-09-02

Written Confirmation Number : WC-0074

Address of the Firm : 294, G.I.D.C. Estate, Ankleshwar, Dist. -Bharuch-393002, Gujarat State, India

blank

04

Hetero Drugs

India
PEGS Boston Summit
Not Confirmed
arrow

Hetero Drugs

India
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride USP/Ph.Eur

Date of Issue : 2022-09-30

Valid Till : 2025-08-08

Written Confirmation Number : WC-0066

Address of the Firm : Plot No 1, Hetero Infrastructure SEZ Ltd., N. Narasapuram, Anakapalli -531081, A...

blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride USP

Date of Issue : 2023-07-24

Valid Till : 2026-08-23

Written Confirmation Number : WC-0381

Address of the Firm : Address: Plot No. 98-99, Sector-1, Industrial Area Pithampur, Dhar-454775, Madhy...

blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride BP/Ph. Eur

Date of Issue : 2023-07-10

Valid Till : 2025-05-21

Written Confirmation Number : WC-0313

Address of the Firm : SurveyNo.247,Choutuppal, Choutuppal (V),Choutuppal (M),YadadriBhuvanagiri Distri...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Raloxifene hydrochloride

Registrant Name : Alvogen Korea Co., Ltd.

Registration Date : 2020-09-17

Registration Number : 20200917-209-J-745

Manufacturer Name : Dr. Reddy's Laboratories Lim...

Manufacturer Address : Chemical Technical Operations-Unit-II Plot No. 1, 75A, 75B, 105, 110, 111 & 112 Sri V...

Dr Reddy Company Banner

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene hydrochloride

Registrant Name : Medipoem Co., Ltd.

Registration Date : 2025-06-23

Registration Number : 20231218-209-J-1584(A)

Manufacturer Name : Aurore Pharmaceuticals Priva...

Manufacturer Address : Plot No. 35, 36, 38 to 40 & 49 to 51 Phase-IV, IDA, Jeedimetla, Hyderabad Telangana, ...

blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene hydrochloride

Registrant Name : Sam-O Pharmaceutical Co., Ltd.

Registration Date : 2020-08-13

Registration Number : 20200813-209-J-694

Manufacturer Name : Cambrex Profarmaco Milano Sr...

Manufacturer Address : Via Curiel, 34 – 20067 Paullo (Milan) Italy

blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene hydrochloride monohydrate

Registrant Name : Dasan Pharmaceutical Co., Ltd.

Registration Date : 2017-11-07

Registration Number : 20171107-209-J-123

Manufacturer Name : Dasan Pharmaceutical Co., Lt...

Manufacturer Address : 342, Deogamsan-ro, Dogomyeon, Asan-si, Chungcheongnam-do @ 28, Jeyakgongdan 2-gil, Hy...

blank

05

Hanmi Pharmaceutical

South Korea
PEGS Boston Summit
Not Confirmed
arrow

Hanmi Pharmaceutical

South Korea
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene hydrochloride

Registrant Name : Hanmi Fine Chemical Co., Ltd.

Registration Date : 2022-10-24

Registration Number : 20221024-209-J-1389

Manufacturer Name : Hanmi Fine Chemical Co., Ltd...

Manufacturer Address : 57, Gyeongje-ro, Siheung-si, Gyeonggi-do (1248-10)

blank

06

Hetero Drugs

India
PEGS Boston Summit
Not Confirmed
arrow

Hetero Drugs

India
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene hydrochloride

Registrant Name : Seongwoo Chemical Co., Ltd.

Registration Date : 2021-10-14

Registration Number : 20211014-209-J-1021

Manufacturer Name : Hetero Drugs Limited (Unit-I...

Manufacturer Address : Plot No.1, Hetero Infrastructure-SEZ Ltd, N. Narasapuram Village, Nakkapalli Mandal, ...

blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene hydrochloride

Registrant Name : Kyungbo Pharmaceutical Co., Ltd.

Registration Date : 2018-02-27

Registration Number : 20180227-209-J-77

Manufacturer Name : Kyungbo Pharmaceutical Co., ...

Manufacturer Address : 174 Silok-ro, Asan-si, Chungcheongnam-do

blank

08

PEGS Boston Summit
Not Confirmed
arrow

arrow
PEGS Boston Summit
Not Confirmed

Raloxifene hydrochloride

Registrant Name : Engchem Life Sciences Co., Ltd.

Registration Date : 2020-07-16

Registration Number : 20200716-209-J-693

Manufacturer Name : Engchem Life Sciences Co., L...

Manufacturer Address : 59 Biovalley-ro, Jecheon-si, Chungcheongbuk-do

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

RALOXIFENE HYDROCHLORIDE

NDC Package Code : 62704-0115

Start Marketing Date : 1998-01-01

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

RALOXIFENE HYDROCHLORIDE

NDC Package Code : 66039-961

Start Marketing Date : 2025-03-25

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

RALOXIFENE HYDROCHLORIDE

NDC Package Code : 65862-714

Start Marketing Date : 2024-01-10

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (50kg/50kg)

Marketing Category : BULK INGREDIENT

blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

RALOXIFENE HYDROCHLORIDE

NDC Package Code : 65691-0079

Start Marketing Date : 2013-05-06

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (25kg/25kg)

Marketing Category : BULK INGREDIENT

blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

RALOXIFENE HYDROCHLORIDE

NDC Package Code : 12828-0085

Start Marketing Date : 2011-01-03

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

RALOXIFENE HYDROCHLORIDE

NDC Package Code : 63419-0420

Start Marketing Date : 2008-10-30

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

RALOXIFENE HYDROCHLORIDE

NDC Package Code : 49706-1723

Start Marketing Date : 2010-01-08

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

RALOXIFENE HYDROCHLORIDE

NDC Package Code : 65977-0065

Start Marketing Date : 1997-12-09

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

09

Olon S.p.A.

Italy
PEGS Boston Summit
Not Confirmed
arrow

Olon S.p.A.

Italy
arrow
PEGS Boston Summit
Not Confirmed

RALOXIFENE HYDROCHLORIDE

NDC Package Code : 17337-0071

Start Marketing Date : 2019-08-27

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

10

Sicor S.r.l.

Italy
PEGS Boston Summit
Not Confirmed
arrow

Sicor S.r.l.

Italy
arrow
PEGS Boston Summit
Not Confirmed

RALOXIFENE HYDROCHLORIDE

NDC Package Code : 53183-4005

Start Marketing Date : 2010-09-13

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Raloxifene Hydrochloride

About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale
Dr Reddy Company Banner

02

HRV Pharma

India
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content

Raloxifene Hydrochloride

About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...

HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing, manufacturing, and supply services to support partners entering new markets worldwide. HRV Pharma works closely with major pharma and food additive companies and represents over 30 Indian drugmakers, primarily serving Europe, the US, and the Middle East. Headquartered in India, it operates offices in the US, Switzerland, Dubai, Lithuania, and Turkey. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
HRV Global Life Sciences

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride

About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...

Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride

About the Company : Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with...

Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with vast experience across the pharmaceutical value chain, the company is on a mission to become the most preferred partner for pharmaceuticals. At Aurore, we aim to push the boundaries to manufacture and deliver high quality products that can be relied upon by both customers and regulators. Our thrust on rapidly adding capabilities have led us to acquire, integrate and expand our reach across the geographies.
blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride

About the Company : Driven by passion, our pharmaceutical products, expertise and technologies accelerate our customers’ small molecule therapeutics into markets across the world. With over 35 years...

Driven by passion, our pharmaceutical products, expertise and technologies accelerate our customers’ small molecule therapeutics into markets across the world. With over 35 years of API development and manufacturing expertise, a growing team of more than 1,200 experts and a strong presence in the USA and Europe, we are tried and trusted across branded and generic API markets. We put all of our energy and experience into being your partner of choice. We create value for customers through manufacturing excellence, reliable quality and innovative science. Our people are the experts that our customers enjoy working with.
blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride

About the Company : Chieron is a leading manufacturer of niche Active Pharmaceutical Ingredients (APIs) and a trusted CDMO/CMO partner serving global pharmaceutical markets. Established in 2007, the c...

Chieron is a leading manufacturer of niche Active Pharmaceutical Ingredients (APIs) and a trusted CDMO/CMO partner serving global pharmaceutical markets. Established in 2007, the company specializes in cardiovascular and CNS therapeutic segments and holds prestigious approvals, including COS, USFDA, and Korean FDA. With a strong focus on backward integration, innovation, quality, and regulatory compliance, Chieron delivers reliable, cost-effective API and intermediate solutions while supporting customers across Europe, Japan, Korea, and other international markets.
blank

07

Cipla

India
PEGS Boston Summit
Not Confirmed
arrow

Cipla

India
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride

About the Company : Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission i...

Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission is to be a leading global healthcare company which uses technology and innovation to meet everyday needs of all patients. Since inception in 1935, caring has been at the core of everything we do at Cipla. For patients, caring is a promise that we will do whatever it takes to ensure they have continued access to the highest quality medicines at affordable prices; whether a disease affects millions or just a few hundreds.
blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride

About the Company : We believe in attaining the highest levels of customer satisfaction and social welfare with the philosophy of keeping first things first. Our systematic interventions keeping abrea...

We believe in attaining the highest levels of customer satisfaction and social welfare with the philosophy of keeping first things first. Our systematic interventions keeping abreast of new and emerging technologies consistently help us meet and exceed quality standards with significant innovations. At LifeFirst, we strive to maintain our goodwill as one of the key partners of choice with the reputation of delivering consistently high-quality products to the pharmaceutical industry. After all, our fundamental philosophy is to offer unrelenting care and cure worldwide with our innovations.
blank

09

Olon S.p.A

Italy
PEGS Boston Summit
Not Confirmed
arrow

Olon S.p.A

Italy
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride

About the Company : We produce Active Pharmaceutical Ingredients (APIs) providing integrated full-service capabilities. Olon’s ability to develop and manufacture Active Pharmaceutical Ingredients (...

We produce Active Pharmaceutical Ingredients (APIs) providing integrated full-service capabilities. Olon’s ability to develop and manufacture Active Pharmaceutical Ingredients (APIs) in our network of facilities allows clients full access to integrated services resulting in faster production and delivery timelines, with one of the most extensive track records. We rely on synthetic and biological processes both for generic and contract development and the manufacturing market, in a full cGMPs environment, following ICH Q7 compliance.
blank

10

Raks Pharma

India
PEGS Boston Summit
Not Confirmed
arrow

Raks Pharma

India
arrow
PEGS Boston Summit
Not Confirmed

Raloxifene Hydrochloride

About the Company : Founded by a group of highly committed Technocrats in year 2009, today Raks Pharma is a partner of choice for pharmaceutical companies across the globe to source Active Pharmaceuti...

Founded by a group of highly committed Technocrats in year 2009, today Raks Pharma is a partner of choice for pharmaceutical companies across the globe to source Active Pharmaceuticals Ingredients and their intermediates. Till date the company has invested around US $ 50M and has filed 23 US DMFs and 1 CEP with US and European Authority's respectively. The manufacturing facility is also approved by USFDA and WHO. We at Raks are dedicated to develop and manufacture active pharmaceutical ingredients and intermediates. We are committed to create value through intellectual property, quality systems and customer relation across the globe.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

PMC Isochem

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

CAS Number : 84449-81-0

End Use API : Raloxifene Hydrochloride

About The Company : PMC Isochem, acquired by PMC International in 2017, is a CDMO manufacturing cGMP intermediates, APIs, and functional excipients for global pharmaceutical and pe...

PMC Isochem

02

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 84449-80-9

End Use API : Raloxifene Hydrochloride

About The Company : Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in...

blank

03

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 1246815-60-0

End Use API : Raloxifene Hydrochloride

About The Company : TEXLAB INDUSTRIES was established in 1971, manufacturing & trading related business. TEXLAB INDUSTRIES - company launched by Late Shree AMBALAL MISTRY for local...

blank

04

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 63675-74-1

End Use API : Raloxifene Hydrochloride

About The Company : TEXLAB INDUSTRIES was established in 1971, manufacturing & trading related business. TEXLAB INDUSTRIES - company launched by Late Shree AMBALAL MISTRY for local...

blank

05

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 63675-74-1

End Use API : Raloxifene Hydrochloride

About The Company : We believe in attaining the highest levels of customer satisfaction and social welfare with the philosophy of keeping first things first. Our systematic interve...

blank

06

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 63676-22-2

End Use API : Raloxifene Hydrochloride

About The Company : We believe in attaining the highest levels of customer satisfaction and social welfare with the philosophy of keeping first things first. Our systematic interve...

blank

07

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 84449-65-0

End Use API : Raloxifene Hydrochloride

About The Company : We believe in attaining the highest levels of customer satisfaction and social welfare with the philosophy of keeping first things first. Our systematic interve...

blank

08

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 63675-74-1

End Use API : Raloxifene Hydrochloride

About The Company : We believe in attaining the highest levels of customer satisfaction and social welfare with the philosophy of keeping first things first. Our systematic interve...

blank

09

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 63676-22-2

End Use API : Raloxifene Hydrochloride

About The Company : We believe in attaining the highest levels of customer satisfaction and social welfare with the philosophy of keeping first things first. Our systematic interve...

blank

10

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 84449-65-0

End Use API : Raloxifene Hydrochloride

About The Company : We believe in attaining the highest levels of customer satisfaction and social welfare with the philosophy of keeping first things first. Our systematic interve...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Coating Systems & Additives

read-more
read-more

Solubilizers

read-more
read-more

Granulation

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Controlled & Modified Release

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Lubricants & Glidants

read-more
read-more

Topical

read-more
read-more

Parenteral

read-more
read-more

Taste Masking

read-more
read-more

Co-Processed Excipients

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Emulsifying Agents

read-more
read-more

API Stability Enhancers

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Empty Capsules

read-more
read-more

Vegetarian Capsules

read-more
read-more

Rheology Modifiers

read-more
read-more

Coloring Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ANALYTICAL

Upload your methods for free, ask us

ABOUT THIS PAGE

Looking for 82640-04-8 / Raloxifene Hydrochloride API manufacturers, exporters & distributors?

Raloxifene Hydrochloride manufacturers, exporters & distributors 1

96

PharmaCompass offers a list of Raloxifene Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Raloxifene Hydrochloride manufacturer or Raloxifene Hydrochloride supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Raloxifene Hydrochloride manufacturer or Raloxifene Hydrochloride supplier.

API | Excipient name

Raloxifene Hydrochloride

Synonyms

82640-04-8, Raloxifene hcl, Evista, Keoxifene hydrochloride, Keoxifene, Optruma

Cas Number

82640-04-8

Unique Ingredient Identifier (UNII)

4F86W47BR6

About Raloxifene Hydrochloride

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Raloxifene HCl Manufacturers

A Raloxifene HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Raloxifene HCl, including repackagers and relabelers. The FDA regulates Raloxifene HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Raloxifene HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Raloxifene HCl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Raloxifene HCl Suppliers

A Raloxifene HCl supplier is an individual or a company that provides Raloxifene HCl active pharmaceutical ingredient (API) or Raloxifene HCl finished formulations upon request. The Raloxifene HCl suppliers may include Raloxifene HCl API manufacturers, exporters, distributors and traders.

click here to find a list of Raloxifene HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Raloxifene HCl USDMF

A Raloxifene HCl DMF (Drug Master File) is a document detailing the whole manufacturing process of Raloxifene HCl active pharmaceutical ingredient (API) in detail. Different forms of Raloxifene HCl DMFs exist exist since differing nations have different regulations, such as Raloxifene HCl USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Raloxifene HCl DMF submitted to regulatory agencies in the US is known as a USDMF. Raloxifene HCl USDMF includes data on Raloxifene HCl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Raloxifene HCl USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Raloxifene HCl suppliers with USDMF on PharmaCompass.

Raloxifene HCl JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Raloxifene HCl Drug Master File in Japan (Raloxifene HCl JDMF) empowers Raloxifene HCl API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Raloxifene HCl JDMF during the approval evaluation for pharmaceutical products. At the time of Raloxifene HCl JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Raloxifene HCl suppliers with JDMF on PharmaCompass.

Raloxifene HCl KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Raloxifene HCl Drug Master File in Korea (Raloxifene HCl KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Raloxifene HCl. The MFDS reviews the Raloxifene HCl KDMF as part of the drug registration process and uses the information provided in the Raloxifene HCl KDMF to evaluate the safety and efficacy of the drug.

After submitting a Raloxifene HCl KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Raloxifene HCl API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Raloxifene HCl suppliers with KDMF on PharmaCompass.

Raloxifene HCl CEP

A Raloxifene HCl CEP of the European Pharmacopoeia monograph is often referred to as a Raloxifene HCl Certificate of Suitability (COS). The purpose of a Raloxifene HCl CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Raloxifene HCl EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Raloxifene HCl to their clients by showing that a Raloxifene HCl CEP has been issued for it. The manufacturer submits a Raloxifene HCl CEP (COS) as part of the market authorization procedure, and it takes on the role of a Raloxifene HCl CEP holder for the record. Additionally, the data presented in the Raloxifene HCl CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Raloxifene HCl DMF.

A Raloxifene HCl CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Raloxifene HCl CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Raloxifene HCl suppliers with CEP (COS) on PharmaCompass.

Raloxifene HCl WC

A Raloxifene HCl written confirmation (Raloxifene HCl WC) is an official document issued by a regulatory agency to a Raloxifene HCl manufacturer, verifying that the manufacturing facility of a Raloxifene HCl active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Raloxifene HCl APIs or Raloxifene HCl finished pharmaceutical products to another nation, regulatory agencies frequently require a Raloxifene HCl WC (written confirmation) as part of the regulatory process.

click here to find a list of Raloxifene HCl suppliers with Written Confirmation (WC) on PharmaCompass.

Raloxifene HCl NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Raloxifene HCl as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Raloxifene HCl API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Raloxifene HCl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Raloxifene HCl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Raloxifene HCl NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Raloxifene HCl suppliers with NDC on PharmaCompass.

Raloxifene HCl GMP

Raloxifene HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Raloxifene HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Raloxifene HCl GMP manufacturer or Raloxifene HCl GMP API supplier for your needs.

Raloxifene HCl CoA

A Raloxifene HCl CoA (Certificate of Analysis) is a formal document that attests to Raloxifene HCl's compliance with Raloxifene HCl specifications and serves as a tool for batch-level quality control.

Raloxifene HCl CoA mostly includes findings from lab analyses of a specific batch. For each Raloxifene HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Raloxifene HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (Raloxifene HCl EP), Raloxifene HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Raloxifene HCl USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty